Concord Hospital Trust Sets Goal to Raise $200K for New Prostate Cancer Diagnostic Technology Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death among men in New Hampshire. Each year, Concord Hospital Center for Urologic Care conducts on average 300 prostate biopsies. In 2016, there were 132 prostate cancer diagnoses. The current diagnosis protocol is not perfect; it exposes too many men to needless biopsies and is also often unable to isolate suspected lesions, which may result in small cancers being missed. New technology is now available that fuses ultrasound imaging and Magnetic Resonance Imaging (MRI) to aid prostate cancer diagnosis. Blending these technologies creates a detailed 360 degree prostate roadmap to identify possible disease, together with specific target areas for possible biopsy. The result is fewer and more accurate biopsies versus the “shot-in-the-dark” approach (12-24 core biopsies) and the saturation approach (80-90 core biopsies). Any man who has undergone a prostate biopsy or knows someone who has will understand that this is a technology worth investing in. The benefits of this state-of-the-art approach to prostate biopsies are many, including: “Real time” imaging; Pinpoint identification of disease and disease stage; Minimal needles; Reduced infection risk; Customized treatment plans. We have set a goal to raise $200,000 of the $274,490 needed to bring this technology to support the Central New Hampshire population served by the Center for Urologic Care. We would be the first hospital in New Hampshire to have this equipment, which also furthers our being recognized as a regional referral resource.